Prospera Financial Services Inc raised its holdings in Pfizer Inc. (NYSE:PFE) by 1.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,493 shares of the biopharmaceutical company’s stock after buying an additional 795 shares during the quarter. Prospera Financial Services Inc’s holdings in Pfizer were worth $1,684,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. Csenge Advisory Group lifted its position in Pfizer by 41.1% during the 1st quarter. Csenge Advisory Group now owns 21,407 shares of the biopharmaceutical company’s stock worth $699,000 after buying an additional 6,236 shares in the last quarter. Dubuque Bank & Trust Co. lifted its position in Pfizer by 4.0% during the 1st quarter. Dubuque Bank & Trust Co. now owns 45,356 shares of the biopharmaceutical company’s stock valued at $1,480,000 after purchasing an additional 1,746 shares during the period. Berkeley Capital Partners LLC lifted its position in Pfizer by 65.5% during the 1st quarter. Berkeley Capital Partners LLC now owns 60,872 shares of the biopharmaceutical company’s stock valued at $1,987,000 after purchasing an additional 24,091 shares during the period. Nicolet Advisory Services LLC lifted its position in Pfizer by 53.4% during the 1st quarter. Nicolet Advisory Services LLC now owns 26,827 shares of the biopharmaceutical company’s stock valued at $876,000 after purchasing an additional 9,339 shares during the period. Finally, Hamilton Wealth LLC lifted its position in Pfizer by 41.8% during the 1st quarter. Hamilton Wealth LLC now owns 135,731 shares of the biopharmaceutical company’s stock valued at $4,430,000 after purchasing an additional 39,978 shares during the period. Institutional investors own 70.20% of the company’s stock.
A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. cut their target price on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Monday, June 1st. Piper Sandler upped their target price on shares of Pfizer from $18.50 to $24.00 in a research report on Friday, June 26th. ValuEngine downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a research report on Thursday, July 30th. Morgan Stanley upped their target price on shares of Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Finally, Royal Bank of Canada restated a “buy” rating and set a $43.00 target price on shares of Pfizer in a research report on Monday, July 20th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $38.95.
NYSE:PFE traded up $0.44 during trading hours on Thursday, reaching $38.70. 751,395 shares of the stock were exchanged, compared to its average volume of 29,075,008. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $40.97. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.42 and a quick ratio of 1.16. The firm has a 50 day moving average of $36.75 and a 200 day moving average of $35.63. The stock has a market cap of $213.16 billion, a PE ratio of 15.31, a PEG ratio of 3.09 and a beta of 0.74.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The firm had revenue of $11.80 billion during the quarter, compared to the consensus estimate of $11.55 billion. During the same quarter in the prior year, the firm posted $0.80 EPS. The business’s revenue was down 11.0% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.89 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 31st will be given a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a yield of 3.93%. The ex-dividend date is Thursday, July 30th. Pfizer’s dividend payout ratio (DPR) is currently 51.53%.
In related news, Director Ronald E. Blaylock acquired 13,000 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was bought at an average price of $38.55 per share, with a total value of $501,150.00. Following the acquisition, the director now owns 4,000 shares in the company, valued at approximately $154,200. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jennifer B. Damico sold 2,181 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $36.13, for a total value of $78,799.53. Following the completion of the sale, the senior vice president now directly owns 7,542 shares of the company’s stock, valued at approximately $272,492.46. The disclosure for this sale can be found here. Corporate insiders own 0.08% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: How big is the FinTech market?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.